Device Trial Radar · NCT00131326
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
Last checked: Nov 20, 2026Latest source record: Jul 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
Not stated
Start
Nov 2003
Primary completion
Not stated
Study completion Apr 2006
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanyNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 18, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.
Conditions
- Osteoarthritis, Hip
- Musculoskeletal Diseases
Interventions
Synvisc (hylan G-F 20)Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain relief
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics
Birmingham, Alabama
John Higginbotham, MD Sports Medicine
Huntsville, Alabama
Affiliated Orthopedic Specialists
Scottsdale, Arizona
29 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.